IVIS Spectrum Imaging System

IVIS 光谱成像系统

基本信息

批准号：
7595434
负责人：
ANNA MOORE
金额：
$ 34.11万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-05-01 至 2010-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7595434
关键词：
Animals Area Arts Biological Testing Bioluminescence Biomedical Research Boston Brain Diseases Cardiovascular Pathology Characteristics Communities Data Detection Development Diabetes Mellitus Emerging Technologies Environment Experimental Models Fluorescence Functional Magnetic Resonance Imaging Funding General Hospitals Image In Vitro Institution Interdisciplinary Study Islets of Langerhans Life Magnetic Resonance Imaging Magnetoencephalography Malignant Neoplasms Massachusetts Modality Multimodal Imaging Mus Operative Surgical Procedures Optics Positron-Emission Tomography Preclinical Drug Evaluation Radiation Relative (related person)Reporter Research Research Project Grants Resolution Resources Signal Transduction Speed System Techniques Time Transplantation bioimaging clinical application cost data acquisition imaging modality in vivo innovation instrumentation light emission molecular imaging nervous system disorder new technology novel optical imaging public health relevance research study success transmission process

项目摘要

DESCRIPTION (provided by applicant): Optical imaging is rapidly becoming one of the most versatile imaging modalities in biomedical research. The advantages of optical imaging compared to other imaging modalities include its non-ionizing low-energy radiation, high sensitivity for detecting objects in the micron range, and continuous data acquisition in real time and in an intact environment. The cost, space, and time demands associated with optical imaging are less than for other imaging modalities, and the speed and relative ease of imaging makes this modality attractive for potential clinical applications. The Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital (MGH) strives to develop and apply breakthrough imaging approaches in clinically meaningful ways. Our continuing success relies on the integration of new and emerging technologies into our existing research imaging repertoire, which includes functional and high-resolution magnetic resonance imaging (fMRI and MRI), magnetoencephalography (MEG), positron emission tomography (PET), and homebuilt functional optical imaging instrumentation. New technologies enhance our ability to validate and interpret data from our existing imaging resources and to combine imaging modalities for novel multimodal imaging applications-capabilities that are particularly needed in the emerging field of molecular imaging. We propose to purchase a state-of-the-art optical imaging system capable of 3D molecular imaging in transmission fluorescence, reflectance fluorescence, and bioluminescence modes in vivo, ex vivo, and in vitro. Significant advantages of the optical techniques possible with this system include the potential for multichannel imaging by using multiple probes with different spectral characteristics; quick, easy, and relatively low-cost rapid testing of biological hypotheses and proofs of principle in living experimental models. Importantly, optical bioluminescence imaging has unique advantages for detection of very low levels of signal because of its virtually background-free light emission. With its ease of operation, short acquisition time (typically 10-60 sec), and potential high-throughput format in vitro (microplates) and in vivo (5 mice, 23 cm FOV), this innovative system also provides high-throughput imaging capabilities. The new optical system will be an important resource for many currently funded biomedical imaging research projects. Major projects include studies on neurodenenerative disorders and brain function, cancer, and pancreatic islets in diabetes and transplantation. With the new in vivo optical imaging system and our existing imaging facilities under one roof, we can feasibly perform in-vivo experiments using one or more imaging modalities in succession, or even in parallel. This system will be an invaluable resource for the rich body of interdisciplinary research at the Martinos center and the larger MGH research community, as well as at other institutions in the greater Boston area. PUBLIC HEALTH RELEVANCE: Acquiring of a state-of-the-art in vivo optical imaging system with fluorescence and bioluminescence capabilities will allow for fast, easy and cheap ways to rapidly test biological hypotheses and proofs of principle in living experimental models, which could be further utilized for in vivo drug screening, development of imaging reporters and versatile animal studies in cancer, neurological disorders, diabetes and cardiovascular pathologies.

描述（由申请人提供）：光学成像正迅速成为生物医学研究中用途最广泛的成像方式之一。与其他成像方式相比，光学成像的优点包括其非电离低能辐射，对微米范围内检测对象的高灵敏度以及实时和完整环境中的连续数据获取。与光学成像相关的成本，空间和时间需求小于其他成像方式，并且成像的速度和相对易于速度使这种方式对潜在的临床应用有吸引力。马萨诸塞州综合医院（MGH）的Athinoula A. Martinos生物医学成像中心致力于以临床意义的方式开发和应用突破性成像方法。我们的持续成功依赖于将新技术和新兴技术整合到我们现有的研究成像曲目中，其中包括功能和高分辨率磁共振成像（fMRI和MRI），磁脑电图（MEG），Potitron SusistionSussighon possuction possogragy（PET）以及Home Buililt功能光学成像仪器。新技术增强了我们从现有成像资源中验证和解释数据的能力，并结合成像模式，以实现新型多模式成像应用程序障碍，这在分子成像的新兴领域中尤其需要。我们建议在透射荧光，反射率荧光和生物发光模式中购买能够在体内，Ex Vivo和体外进行3D分子成像的最先进的光学成像系统。通过使用多个具有不同光谱特征的探针，该系统可能具有光学技术的显着优势包括多通道成像的潜力。生物学假设的快速，容易且相对较低的成本快速测试和实验模型中的原理证明。重要的是，由于其几乎没有背景的光发射，光学发光成像具有检测非常低的信号水平的独特优势。凭借其易于操作，收购时间较短（通常为10-60秒），并且在体外（微板岩）和体内（5小鼠，23厘米FOV）的潜在高通量格式，此创新系统还提供了高通量成像功能。对于许多当前资助的生物医学成像研究项目，新的光学系统将成为重要的资源。主要项目包括有关糖尿病和移植中神经氨酸疾病和脑功能，癌症和胰岛的研究。借助新的体内光学成像系统和我们现有的成像设施，我们可以使用一种或多种成像方式连续甚至并行地进行体内实验。对于马提尼斯中心和更大的MGH研究社区以及大波士顿地区的其他机构，该系统将是丰富的跨学科研究团体的宝贵资源。 PUBLIC HEALTH RELEVANCE: Acquiring of a state-of-the-art in vivo optical imaging system with fluorescence and bioluminescence capabilities will allow for fast, easy and cheap ways to rapidly test biological hypotheses and proofs of principle in living experimental models, which could be further utilized for in vivo drug screening, development of imaging reporters and versatile animal studies in cancer, neurological disorders, diabetes and cardiovascular病理。

项目成果

期刊论文数量（20）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Image-guided breast tumor therapy using a small interfering RNA nanodrug.

DOI：
10.1158/0008-5472.can-10-2070
发表时间：
2010-10-01
期刊：
Cancer research
影响因子：
11.2
作者：
Kumar M;Yigit M;Dai G;Moore A;Medarova Z
通讯作者：
Medarova Z

Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma.

DOI：
10.1002/ijc.28499
发表时间：
2014-04-01
期刊：
INTERNATIONAL JOURNAL OF CANCER
影响因子：
6.4
作者：
Ghosh, Subrata K.;Yigit, Mehmet V.;Uchida, Masashi;Ross, Alana W.;Barteneva, Natalie;Moore, Anna;Medarova, Zdravka
通讯作者：
Medarova, Zdravka

Non-conjugated small molecule FRET for differentiating monomers from higher molecular weight amyloid beta species.